Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (15492)	9/24/1998 10:41:00 AM
From: TWICK	Respond to of 120523

EGGS - What's your take on it. There's a nice size short interest on it and YHOO and e.bay seem to be helping it move. Worth a play to double digits ? TWICK

To: Jenna who wrote (15492)	9/24/1998 11:20:00 AM
From: Maxwell Fashola	Read Replies (2) \| Respond to of 120523

Jenna, I bought more CCIJA at 4 1/4. I believe next week will be very good for bank stocks. I bought YHQVC at 6 1/2 out at 9 1/2 all in 15 minutes.

To: Jenna who wrote (15492)	9/25/1998 10:32:00 AM
From: Jenna	Respond to of 120523

GILD ... nice company..FIBR moving, SRCM.. just had MACD and stochastic breakout.. 9/25/98 - New weapons in fight against flu SAN DIEGO, Sept. 25 (UPI) _ A report being released in San Diego says two companies have developed what researchers call the most potent drugs yet for the treatment of influenza. In tests, the drugs proved themselves capable of easing the symptoms caused by all strains of the flu and shortening the duration of the worst symptoms _ fever, headache and muscle pain. One of the drugs, GS4104, has also been shown to be very effective in preventing flu among people who have not been vaccinated. Neither has been shown to have great risk for side effects. Researchers will present the first results from clinical trials with the drugs at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Relenza was developed by Glaxo Wellcome Inc. and the other drug, known as GS4104, was developed by F. Hoffman-La Roche and Gilead Sciences. Flu affects between 26 million and 55 million people in the United States every year. About 40,000 die of it _ primarily people who are very young or very old. The new drugs could be on the market for the 1999-2000 flu season. _- Copyright 1998 by United Press International. All rights reserved. _-